Sarepta Therapeutics Announces Positive Vote at US FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy | Sarepta Therapeutics, Inc. – Investor Relations | Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Positive Vote at US FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy | Sarepta Therapeutics, Inc.Investor Relations | Sarepta Therapeutics, Inc.
FDA Duchenne Muscular Dystrophy Gene Therapy: ShotsNPR
Sarepta Gene Therapy FDA Advisory Panel Follow-UpSTAT
FDA advisers narrowly vote in favor of Sarepta’s DMD gene therapyFierceBiotech
For patients with Sarepta and muscular dystrophy, Friday’s FDA hearing was crucialBarrons
See full coverage on Google News